Head-To-Head Comparison: Climb Bio (CLYM) vs. The Competition

Climb Bio (NASDAQ:CLYM) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Climb Bio to related businesses based on the strength of its risk, dividends, institutional ownership, earnings, profitability, analyst recommendations and valuation.

Volatility and Risk

Climb Bio has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s peers have a beta of 3.71, indicating that their average stock price is 271% more volatile than the S&P 500.

Profitability

This table compares Climb Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Valuation and Earnings

This table compares Climb Bio and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-0.90
Climb Bio Competitors	$9.59 billion	$147.39 million	-5.45

Climb Bio’s peers have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Climb Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7782	21206	48908	1233	2.55

Climb Bio currently has a consensus price target of $10.00, suggesting a potential upside of 420.83%. As a group, “Pharmaceutical preparations” companies have a potential upside of 185.43%. Given Climb Bio’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Climb Bio is more favorable than its peers.

Insider & Institutional Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Climb Bio beats its peers on 7 of the 13 factors compared.

Climb Bio Company Profile

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.